![Rachelle Jacques](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Rachelle Jacques
Chairman at
CORBUS PHARMACEUTICALS HOLDINGS, INC.
Net worth: 1 M $ as of 31/05/2026
Profile
Rachelle Suzanne Jacques is Chairman at Corbus Pharmaceuticals Holdings, Inc. since 2025 and Director at Corbus Pharmaceuticals, Inc. since 2019.
Ms. Jacques serves as Independent Non-Executive Director at uniQure NV since 2021.
Ms. Jacques is a Trustee at Alma College and a Member of the Action for Equality Task Force at the Alliance for Regenerative Medicine.
Former roles include Chief Executive Officer at Enzyvant, Inc. and Enzyvant Therapeutics, Inc. from 2019 to 2022.
Ms. Jacques was Director at Viela Bio, Inc. from 2020 to 2021 and Director at Akari Therapeutics Plc in 2024.
Ms. Jacques was Vice President-Finance & US BioScience Business at Baxter International, Inc. Ms. Jacques was Senior Vice President-Global Complement Franchise at Alexion Pharmaceuticals, Inc. from 2017 to 2019.
Ms. Jacques worked as a Financial Auditor at Ernst & Young LLP and Deloitte & Touche LLP.
Ms. Jacques was Vice President-US Hematology Marketing at Shire Plc from 2016 to 2017 and at Baxalta, Inc. from 2016 to 2017.
Education includes undergraduate studies at Alma College.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
UNIQURE N.V. 0.05% | 11/06/2026 | 33,903 ( 0.05% ) | 967 253 $ | 31/05/2026 |
| 19/05/2026 | 7,583 ( 0.04% ) | 59 982 $ | 31/05/2026 | |
| 31/12/2025 | 306,146,000 ( 0.58% ) | 3 061 $ | 31/05/2025 |
Rachelle Jacques active positions
| Companies | Position | Start |
|---|---|---|
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Chairman | 15/05/2025 |
| UNIQURE N.V. | Director/Board Member | 21/10/2021 |
Corbus Pharmaceuticals, Inc.
 Corbus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Director/Board Member | 01/04/2019 |
Alliance for Regenerative Medicine
 Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Corporate Officer/Principal | - |
Alma College
 Alma College Other Consumer ServicesConsumer Services Functions as a College/University | Director/Board Member | - |
Former positions of Rachelle Jacques
| Companies | Position | End |
|---|---|---|
| AKARI THERAPEUTICS, PLC | Chief Executive Officer | 25/04/2024 |
Enzyvant, Inc.
 Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Chief Executive Officer | 11/03/2022 |
Enzyvant Therapeutics, Inc.
 Enzyvant Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for treatment of rare diseases | Chief Executive Officer | 01/03/2022 |
| VIELA BIO, INC. | Director/Board Member | 15/03/2021 |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Rachelle Jacques
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
60
1st degree connections
15
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 15 |
|---|---|
Baxter International, Inc.
 Baxter International, Inc. Medical SpecialtiesHealth Technology Produces and supplies medical products, healthcare systems, therapies and pharmaceuticals & provide kidney care services | Health Technology |
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
Ernst & Young LLP
 Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Provides assurance, auditing, tax, legal, technology and consulting & managed services | Commercial Services |
Shire Plc
 Shire Plc Pharmaceuticals: MajorHealth Technology Develops and markets medicines for patients with rare diseases | Health Technology |
Corbus Pharmaceuticals, Inc.
Corbus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Baxalta, Inc.
 Baxalta, Inc. Pharmaceuticals: MajorHealth Technology Engages in research, development and manufacture of therapies and biopharmaceutical products | Health Technology |
Deloitte & Touche LLP
 Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Provides auditing, financial advisory and tax consulting services | Commercial Services |
Alma College
Alma College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alliance for Regenerative Medicine
Alliance for Regenerative Medicine Medical/Nursing ServicesHealth Services Promotes legislative, regulatory and reimbursement initiatives for regenerative medicine | Health Services |
uniQure NV
 uniQure NV BiotechnologyHealth Technology Engages in the discovery, development and commercialization of gene therapies products | Health Technology |
Corbus Pharmaceuticals Holdings, Inc.
 Corbus Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases | Health Technology |
Akari Therapeutics Plc
 Akari Therapeutics Plc BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops therapies for autoimmune and inflammatory diseases | Health Technology |
Viela Bio, Inc.
 Viela Bio, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biotechnology company that develops treatments for inflammation and autoimmune diseases | Health Technology |
Enzyvant, Inc.
Enzyvant, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceutical products | Health Technology |
Enzyvant Therapeutics, Inc.
Enzyvant Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutics for treatment of rare diseases | Health Technology |
- Stock Market
- Insiders
- Rachelle Jacques
